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 Gholson Lyon’s lab focuses on analyzing human genetic variation and its role in severe 
neuropsychiatric disorders and rare diseases, including intellectual disability, autism, and schizophrenia. By 
recruiting large groups of related individuals living in the same geographic location (e.g., Utah), Lyon’s lab can 
study the breadth and depth of genetic variants in a similar environmental background. Using the exome—the 
parts of the genome that code for protein—and whole-genome sequencing, the lab looks for mutations that 
segregate with syndromes in the various populations, and the lab undertakes comprehensive functional studies 
of many of the newly identified mutations. 
 
Ogden Syndrome and the amino-terminal acetylation of proteins, with Max Doerfel, Yiyang Wu, Ronen 
Marmorstein (Philadelphia, PA), Thomas Arnesen (Norway), Nathalie Reuter (Norway), Petra van Damme 
(Belgium) 
 More than 85 % of human proteins are acetylated at their N-terminal amino group, hence, N-terminal 
acetylation (NTA) is one of the most abundant modifications of eukaryotic proteins. Despite its discovery more 
than 30 years ago, very little is known about the cellular effects/functions of this modification. In humans, 6 
distinct N-terminal amino-acetyltransferases (NATs) catalyze the transfer of an acetyl group from acetyl-CoA to 
the Na-terminal amino group of their specific target proteins. The major human acetyltransferase, NatA, 
consists of an auxiliary subunit, Naa15, and a catalytic active subunit, Naa10. We have previously described 
two families with a lethal X-linked disorder of infancy called Ogden syndrome. This disorder comprises a 
distinct combination of an aged appearance, craniofacial anomalies, hypotonia, global developmental delays, 
cryptorchidism and cardiac arrhythmias. Using X chromosome exon sequencing, we identified a c.109T>C 
(p.Ser37Pro) variant in Naa10 as contributing to this disease. Biochemical analysis and immunoprecipitation 
assays in combination with LCMS demonstrated a reduced catalytic capacity and revealed an impaired binding 
of the S37P mutant towards specific interaction partners, including Naa15 and Naa50. Analysis of the N-
terminal acetylome of patient cells revealed a decreased acetylation of a subset of NatA substrates, indicating 
that a reduced binding capability and an affected enzymatic activity of the Naa10 S37P mutation is a prominent 
feature in Ogden Syndrome. Characterization of NAA10/NAA15 knockout yeast strains revealed various 
phenotypes, including growth defects at elevated temperatures and altered sensitivity towards cytotoxic 
stresses. These effects could be rescued by overexpressing human wild type Naa15/Naa10 from plasmids; 
however, overexpressing mutant Naa15/Naa10 S37P only partially rescue these effects. Interestingly, 
introduction of both human Naa15/Naa10 wt and S37P mutant into the endogenous locus of the corresponding 
yeast genes failed to reverse the effects. We also continued our efforts with establishing induced pluripotent 
stem cells (iPSCs) from skin fibroblasts from one of the boys with Ogden Syndrome, and we are also 
establishing knockin mice containing the mutation of interest in NAA10. Ongoing work will focus on 
characterizing the cells and mice. 
 
RykDax Syndrome: Characterization and Analysis of an Idiopathic Intellectual Disability Syndrome, 
with Jason O’Rawe, Yiyang Wu, Han Fang, Laura Jimenez Barron, Ed Yang (Boston), Alan Rope (Oregon) 
and Jeffrey Swensen  (Arizona), Reid Robison (Utah), Kai Wang (California) 
 We worked on the discovery of a new genetic syndrome, RykDax syndrome, driven by a whole genome 
sequencing study for one family from Utah with two affected male brothers, presenting with severe intellectual 
disability (ID), a characteristic intergluteal crease, and very distinctive facial features, including a broad, 
upturned nose, sagging cheeks, downward sloping palpebral fissures, prominent periorbital ridges, deep-set 
eyes, relative hypertelorism, thin upper lip, a high-arched palate, prominent ears with thickened helices, and a 
pointed chin. This Caucasian family was recruited from Utah, USA, and Illumina-based WGS was performed 
on 10 members of this family, with additional Complete Genomics-based WGS performed on the nuclear 
portion of the family (mother, father and the two affected males). Using WGS datasets from 10 members of this 
family, we could increase the reliability of the biological inferences with an integrative bioinformatic pipeline. In 
combination with insights from clinical evaluations and medical diagnostic analyses, these DNA sequencing 
data were used in the study of three plausible genetic disease models that might uncover genetic contribution 
to the syndrome. We found a 2 to 5-fold difference in the number of variants detected as being relevant for 
various disease models when using different sets of sequencing data and analysis pipelines. We derived 
greater accuracy when more pipelines were used in conjunction with data encompassing a larger portion of the 
family, with the number of putative de-novo mutations being reduced by 80%, due to false negative calls in the 
parents. The boys carry a maternally inherited missense variant in a X-chromosomal gene TAF1, which we 
consider as disease relevant. We took a “genotype-first” approach to find other families with variants in TAF1 
and containing individuals having a remarkably similar clinical presentation. TAF1 is the largest subunit of the 
general transcription factor IID (TFIID) multi-protein transcription complex, and our results have implicated 
mutations in TAF1 as playing a critical role in the development of this new intellectual disability syndrome. We 
published the mutation as part of a paper developing SeqHBase, described below, and we also posted a 
preprint with much more detailed clinical description to the BioRxiv preprint server, while we continue 
searching for mutations in TAF1 in additional families. 
 
Development of comprehensive whole genome sequencing analysis pipelines, with Han Fang, Jason 
O’Rawe, Laura Jimenez Barron, Yiyang Wu, Michael Schatz, Giuseppe Narzisi, Kai Wang (California), Max He 
(Wisconsin).  
 We continued developing various bioinformatics approaches for the analysis of exome and whole 
genome sequencing data. For example, in one project, we showed that the accuracy of detection of small 
insertions and deletions (indels) is greater when using whole genome sequencing versus exon capture and 
sequencing. We also calculated that 60X WGS depth of coverage from the Illumina HiSeq platform is needed 
to recover 95% of indels detected by Scalpel. While this is higher than current sequencing practice, we 
proposed that the deeper coverage may save total project costs because of the greater accuracy and 
sensitivity. Finally, we investigated sources of INDEL errors (e.g., capture deficiency, PCR amplification, 
homopolymers). We reported over the past 12 months the results of several other ongoing bioinformatics 
projects as well, as shown in the below publications. For example, we developed SeqHBase, a big data-based 
toolset for analysing family-based sequencing data to detect de novo, inherited homozygous or compound 
heterozygous mutations that may be disease contributory. We demonstrated SeqHBase’s high efficiency and 
scalability, which is necessary, as WGS and WES are rapidly becoming standard methods to study the 
genetics of familial disorders. We also recently published an opinion piece regarding the current state of 
uncertainty quantification in DNA sequencing applications, and we proposed methods that can be used for 
accounting and propagating these errors and their uncertainties through subsequent calculations. 
 
Summarizing the state of human genetics, including the genetic architecture of human disease, with 
Jason O’Rawe. 
 We prepared a comprehensive book chapter summarizing the current state of human genetics, and we 
continue to expand upon this work. In brief, there are ~12 billion nucleotides in every cell of the human body, 
and there are ~25-100 trillion cells in each human body. Given somatic mosaicism, epigenetic changes and 
environmental differences, no two human beings are the same, particularly as there are only ~7 billion people 
on the planet. One of the next great challenges for studying human genetics will be to acknowledge and 
embrace complexity. Every human is unique, and the study of human disease phenotypes (and phenotypes in 
general) will be greatly enriched by moving from a deterministic to a more stochastic/probabilistic model. The 
dichotomous distinction between ‘simple’ and ‘complex’ diseases is completely artificial, and we argue instead 
for a model that considers a spectrum of diseases that are variably manifesting in each person. The rapid 
adoption of whole genome sequencing (WGS) and the Internet-mediated networking of people promise to yield 
more insight into this century-old debate. Comprehensive ancestry tracking and detailed family history data, 
when combined with WGS or at least cascade-carrier screening, might eventually facilitate a degree of genetic 
prediction for some diseases in the context of their familial and ancestral etiologies.  However, it is important to 
remain humble, as our current state of knowledge is not yet sufficient, and in principle, any number of 
nucleotides in the genome, if mutated or modified in a certain way and at a certain time and place, might 
influence some phenotype during embryogenesis or postnatal life. 
 
Expanding collection and sequencing of other rare genetic syndromes, with Jason O’Rawe, Yiyang Wu, 
Han Fang, Laura Jimenez Barron, Margaret Yoon, Ivan Iossifov, Reid Robison (Utah), Kai Wang (California) 
Alan Rope  (Oregon), and others. 
 We continue to meet and collect many families in Utah and elsewhere with very rare, idiopathic genetic 
syndromes. The total number of DNA samples collected to date is approaching 2000, and this includes 
detailed phenotyping information. Some of these samples have undergone exome or whole genome 
sequencing, and we are currently analyzing 18 whole genomes and 35 exomes generated as part of this 
project. This includes the ongoing analysis of whole genomes from 3 families with singleton cases of autism, 
being performed in collaboration with Ivan Iossifov at CSHL, and an analysis of nine whole genomes from a 
pedigree with Prader–Willi Syndrome (PWS), Hereditary Hemochromatosis, Familial Dysautonomia (FD), and 
Tourette Syndrome. We did publish about one case in China where two siblings both began to develop 
idiopathic progressive cognitive decline starting from age six, and were suspected to have an undiagnosed 
neurological disease. Initial clinical assessments included review of medical history, comprehensive physical 
examination, genetic testing for metabolic diseases, blood tests and brain imaging. We performed exome 
sequencing with Agilent SureSelect exon capture and Illumina HiSeq2000 platform, followed by variant 
annotation and selection of rare, shared mutations that fit a recessive model of inheritance. To assess 
functional impacts of candidate variants, we performed extensive biochemical tests in blood and urine, and 
examined their possible roles by protein structure modeling. Exome sequencing identified NAGLU as the most 
likely candidate gene with compound heterozygous mutations (chr17:40695717C>T and chr17:40693129A>G 
in hg19 coordinate). Sanger sequencing confirmed the recessive patterns of inheritance, leading to a genetic 
diagnosis of Sanfilippo syndrome (mucopolysaccharidosis IIIB). Biochemical tests confirmed the complete loss 
of activity of alpha-N-acetylglucosaminidase (encoded by NAGLU) in blood, as well as significantly elevated 
dermatan sulfate and heparan sulfate in urine. Structure modeling revealed the mechanism on how the two 
variants affect protein structural stability. This successful diagnosis of a rare genetic disorder with an atypical 
phenotypic presentation confirmed that such “genotype-first” approaches can particularly succeed in areas of 
the world with insufficient medical genetics expertise and with cost-prohibitive in-depth phenotyping 
 
Writing policy and opinion pieces in genomic medicine, with Carol Barash and others. 
The PI is an ongoing advocate for open access and data sharing, along with assisting with efforts at 
CSHL Press to roll out new initiatives, such as the BioRxiv preprint server and the new journal, Molecular Case 
Studies, which is designed to make it easier to publish and share the underlying data from single cases, 
families or small cohorts of human conditions. 
 
 
Collaborating on genetics of Tourette Syndrome, with the Tourette Syndrome Association International 
Consortium for Genetics.  
 The PI continues to collaborate on this international effort to understand the genetics of Tourette 
Syndrome. Psychiatric comorbidity is common in Tourette syndrome (TS); when present, these conditions 
typically cause more distress and impairment than do tics. High rates of attention-deficit/hyperactivity disorder 
(ADHD) and obsessive-compulsive disorder (OCD) are well documented and thought to be core components 
of the TS phenotype; however, few studies have fully characterized other comorbidities. We therefore 
characterized the prevalence and impact of psychiatric comorbidity in a large sample of individuals with TS and 
their family members. The lifetime prevalence of comorbid psychiatric disorders, their heritabilities, and ages of 
risk were determined in participants with TS (N=1,374). The lifetime prevalence of any psychiatric comorbidity 
was 85.7%; 57.7% of participants had ≥2 psychiatric disorders. The mean number of lifetime comorbid 
diagnoses was 2.1. Prevalence of mood, anxiety, and disruptive behavior disorders was ~30%. The age of 
greatest risk for most psychiatric disorders was 4 to 10 years, except eating and substance use disorders, 
which begin in adolescence. TS was associated with increased risk of anxiety and decreased risk of substance 
use disorders; high rates of mood disorders among participants with TS may be accounted for by comorbid 
OCD. Parental history of ADHD was associated with a higher burden of non-OCD, non-ADHD psychiatric 
disorders.  Genetic correlations between TS and mood, anxiety, and disruptive behavior disorders were better 
accounted for by ADHD and, for mood disorders, by OCD. This study confirmed that psychiatric comorbidities 
begin early in life and are extremely common among individuals with TS, and demonstrates that some may be 
mediated by the presence of comorbid OCD or ADHD.  
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